LWM
RNAM

Liberty Wealth Management’s Avidity Biosciences RNAM Stock Holding History

Liberty Wealth Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-300
Closed -$7K – 892
2021
Q3 		$7K Hold
300
– – ﹤0.01% 890
2021
Q2 		$7K Buy
+300
New +$6.98K ﹤0.01% 733

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Liberty Wealth Management's RNAM Position: Q4 2021 in Review

Liberty Wealth Management sold out of Avidity Biosciences (RNAM) in Q4 2021, closing a stake of 300 shares — an estimated $7K sold.

Liberty Wealth Management first reported a position in RNAM in Q2 2021 and held it in 2 quarters. The position peaked at $7K in Q3 2021. 107 funds tracked by Wall St. Rank hold RNAM as of Q4 2021.

  • Liberty Wealth Management reported no remaining Avidity Biosciences position as of Q4 2021 after selling out during the quarter.
  • Liberty Wealth Management sold 300 Avidity Biosciences shares in Q4 2021, an estimated $7K.
  • Liberty Wealth Management first reported a position in Avidity Biosciences in Q2 2021 and held it in 2 quarters.
  • Liberty Wealth Management's Avidity Biosciences position peaked at $7K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2021.

Based on Liberty Wealth Management's 13F filing for Q4 2021, filed 15 Feb 2022.